NANO-OJAS Trademark

Trademark Overview


On Thursday, May 1, 2014, a trademark application was filed for NANO-OJAS with the United States Patent and Trademark Office. The USPTO has given the NANO-OJAS trademark a serial number of 86268581. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, September 17, 2021. This trademark is owned by NANORX INC.. The NANO-OJAS trademark is filed in the Pharmaceutical Products category with the following description:

Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the ...
nano-ojas

General Information


Serial Number86268581
Word MarkNANO-OJAS
Filing DateThursday, May 1, 2014
Status710 - CANCELLED - SECTION 8
Status DateFriday, September 17, 2021
Registration Number4686043
Registration DateTuesday, February 10, 2015
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 30, 2014

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesAnalgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of hypertension; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and pharmaceutical purposes; Therapeutic pharmaceutical for the treatment of obesity

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, September 17, 2021
Primary Code005
First Use Anywhere DateWednesday, May 21, 2014
First Use In Commerce DateWednesday, May 21, 2014

Trademark Owner History


Party NameNANORX INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressChappaqua, NY 10514

Party NameNANORX INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressChappaqua, NY 10514

Party NameNANORX INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressChappaqua, NY 10514

Trademark Events


Event DateEvent Description
Friday, September 17, 2021CANCELLED SEC. 8 (6-YR)
Monday, February 10, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, February 10, 2015REGISTERED-PRINCIPAL REGISTER
Saturday, January 3, 2015NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, January 2, 2015ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, December 31, 2014STATEMENT OF USE PROCESSING COMPLETE
Tuesday, November 25, 2014USE AMENDMENT FILED
Tuesday, November 25, 2014TEAS STATEMENT OF USE RECEIVED
Tuesday, November 25, 2014NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 30, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 30, 2014PUBLISHED FOR OPPOSITION
Wednesday, September 10, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 20, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 15, 2014ASSIGNED TO EXAMINER
Thursday, May 15, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, May 5, 2014NEW APPLICATION ENTERED IN TRAM